PTCH1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, PTCH1 overexpression and mutations in CML patients are associated with poor prognosis and primary or secondary resistance to tyrosine kinase inhibitors [19,20,21,22].